CompletedPhase 1NCT05154240

A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects

Studying Idiopathic pulmonary fibrosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
InSilico Medicine Hong Kong Limited
Principal Investigator
Christopher J Wynne, MBChB
New Zealand Clinical Research
Intervention
INS018_055(drug)
Enrollment
78 enrolled
Eligibility
18-55 years · All sexes
Timeline
2022 – 2022

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05154240 on ClinicalTrials.gov

Other trials for Idiopathic pulmonary fibrosis

Additional recruiting or active studies for the same condition.

See all trials for Idiopathic pulmonary fibrosis →

← Back to all trials